BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 316521)

  • 1. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
    Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
    Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Pathol Biol (Paris); 1978; 26(3-4):159-62. PubMed ID: 355984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Sem Hop; 1978 Nov 8-15; 54(37-40):1155-8. PubMed ID: 217096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune status of untreated patients with Hodgkin's disease and prognosis.
    Björkholm M; Wedelin C; Holm G; Ogenstad S; Johansson B; Mellstedt H
    Cancer Treat Rep; 1982 Apr; 66(4):701-9. PubMed ID: 7074640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ["Active" rosettes and skin tests to recall antigens and phytohemagglutinin in 48 patients with non metastatic squamous cell lung carcinoma and before treatment (author's transl)].
    Lang JM; Pauli G; Roeslin N; Bigel P; Bessot JC
    Rev Fr Mal Respir; 1980; 8(1):11-6. PubMed ID: 6970392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persisting lymphocyte deficiences during remission in Hodgkin's disease.
    Björkholm M; Holm G; Mellstedt H
    Clin Exp Immunol; 1977 Jun; 28(3):389-93. PubMed ID: 302164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levamisole in the treatment of Hodgkin's disease.
    Berényi E; Kávai M; Szabolcsi M; Szegedi G
    Acta Med Acad Sci Hung; 1979; 36(2):177-85. PubMed ID: 317549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subpopulations of human T lymphocytes in patients with Hodgkin's disease before and after treatment.
    Karande AA; Gulwani B; Advani SH; Gangal SG
    Neoplasma; 1982; 29(2):149-59. PubMed ID: 6981068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed cutaneous hypersensitivity and blood lymphocyte count in advanced Hodgkin's and non-Hodgkin's lymphomas.
    Gupta S; Seth SK; Udupa KN; Sen PC; Rastogi BL
    Ann Chir Gynaecol; 1980; 69(2):79-83. PubMed ID: 7377739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cellular immunity in patients with Hodgkin's disease: modification induced by incubating lymphocytes with fetal calf serum and Hodgkin's serum].
    Rambotti P; Velardi A; Spinozzi F; Falini B; Martelli MF
    Boll Ist Sieroter Milan; 1979 Mar; 58(1):90-9. PubMed ID: 552840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological study of patients with Hodgkin's disease in long-lasting not-maintained complete remission.
    Gobbi M; Fiacchini M; Tomasini I; Ruggero D; Lauria F; Tura S
    Boll Ist Sieroter Milan; 1977 Mar; 56(2):144-51. PubMed ID: 326273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal natural killer cell activity in Hodgkin's disease patients in remission.
    Douer D; Shaked N; Ramot B
    Clin Exp Immunol; 1987 Sep; 69(3):660-7. PubMed ID: 3665188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease.
    Fisher RI
    Cancer Treat Rep; 1982 Apr; 66(4):681-7. PubMed ID: 6210434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on delayed hypersensitivity of patients with Hodgkin's disease during remission.
    Petrov M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1975; 102(1):35-9. PubMed ID: 50967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin's disease.
    Shiftan TA; Caviles AP; Mendelsohn J
    Clin Exp Immunol; 1978 Apr; 32(1):144-52. PubMed ID: 668190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of immunocompetence in Hodgkin's disease.
    Faguet GB
    J Clin Invest; 1975 Oct; 56(4):951-7. PubMed ID: 1159096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hodgkin's disease: study of delayed hypersensitivity of 64 non treated patients. Value of epicutaneous test using croton oil].
    Goasguen J; Leblay R; Guerin D; Le Prise PY; Richier JL
    Sem Hop; 1977 Jan; 53(4):219-25. PubMed ID: 189435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some parameters of cell-mediated immunity in colon cancer patients.
    Markova R; Argirova R; Boeva M
    Neoplasma; 1980; 27(1):43-6. PubMed ID: 6966380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.